Salt Lake City, November 11, 2008 – Lipocine Inc., a specialty pharmaceutical company that uses clinically validated proprietary technologies to address key unmet drug delivery and therapeutic needs, today announced the successful completion of a clinical study that establishes feasibility of the first once-a-day dosing product for Ziprasidone, a leading treatment for schizophrenia and bi-polar disorder.

• Schizophrenia affects 1% of the population and bipolar disorder affects 5.7M adults in the US*.
• Ziprasidone has annual sales approaching $1B** and is considered to be weight neutral relative to other currently available anti-psychotics.
• It has shown potential for use in several other promising CNS indications.

Lipocine plans call for co-development of this exciting opportunity with a marketing partner.

Commenting on this development, President and CEO Mahesh Patel said “our patented Lip’ral®-SSR technology enabled this breakthrough for the ‘once-a-day’ formulation that will improve patient compliance in a meaningful way for schizophrenia and bi-polar disorder sufferers. In addition, sustained release formulations enabled by Lipocine’s Lip’ral® SSR technology offers the potential to improve therapy and side effect profile for drugs such as Ziprasidone.”

 Lip’ral™ and Lip’ral™-SSR are clinically proven oral delivery technologies for water insoluble drugs that improve absorption and can be extended to enable controlled release of insoluble drugs and drugs with pH-sensitive solubility. Multiple patents have been issued and are pending on these proprietary technologies.

 About Lipocine Inc.

Lipocine Inc. is a privately held pharmaceutical company leveraging its proprietary drug delivery technologies to commercialize innovative pharmaceutical products. Lipocine business objectives are to develop products with established drugs that have patient friendly attributes such as faster absorption, lower dose, fewer side effects, less frequent dosing, and no food effect.

www.lipocine.com

*Source: Datamonitor

**Source: Thinkpanmure Healthcare News